# Acute Resistance Exercise Temporarily Reduces Circulating Adiponectin in Trained Young Men: A Pilot Study

**Authors:** Luigi Marano, Marta Mallardo, Ersilia Nigro, Furqan Memon, Viktoriia Fylymonenko, Eleonora Martegani, Sara Missaglia, Ferdinando Cereda, Daniela Tavian, Aurora Daniele

PMC · DOI: 10.3390/biom16020229 · Biomolecules · 2026-02-02

## TL;DR

This study shows that resistance exercise temporarily lowers blood levels of adiponectin, a hormone linked to metabolism and inflammation, in trained young men.

## Contribution

The study reveals that resistance exercise reduces circulating adiponectin regardless of exercise intensity, with no correlation to muscle damage markers.

## Key findings

- Plasma adiponectin significantly decreased 48 hours after resistance exercise in both high and moderate TUT sessions.
- Salivary adiponectin levels remained unchanged despite changes in plasma levels.
- There was no significant correlation between the rise in creatine kinase and the decrease in adiponectin.

## Abstract

Background: Adiponectin is an adipokine with insulin-sensitizing, anti-inflammatory, and cytoprotective properties that also plays a key role in metabolic adaptation to exercise. Although its regulation after resistance exercise has been extensively documented, less is known about its short-term modulation and its correlation with muscle damage markers following resistance training. Methods: Nine resistance-trained young men completed two sessions of total-body resistance exercise: (1) high time under tension (TUT) (5-1-2-1 cadence, to failure; ETS1) and (2) moderate TUT (2-1-2-1 cadence, two repetitions in reserve; ETS2). Plasma and saliva samples were collected before exercise and at 15 min, 24 h, and 48 h after exercise to assess total adiponectin by ELISA. Plasma creatine kinase (CK) and a Visual Analog Scale (VAS) were also measured for muscle soreness. Results: Plasma adiponectin significantly decreased from baseline to 48 h post-exercise in both sessions (p < 0.001), with no differences between the TUT conditions. Salivary adiponectin remained unchanged. Although a significant increase in CK and a decrease in adiponectin were observed at the group level, correlation analysis revealed no significant linear relationship between the magnitude of CK elevation and adiponectin reduction. Conclusions: Overall, these findings support the role of adiponectin as a marker of acute metabolic adaptation to resistance exercise. Acute resistance exercise elicited a time-dependent decrease in circulating adiponectin, irrespective of TUT. The temporal pattern of adiponectin decrease coincided with the rise in muscle damage markers, yet the lack of direct correlation suggests distinct regulatory mechanisms, while the lack of salivary changes underscores the complexity of adipokine regulation in vivo and suggests that saliva is not a reliable indicator of changes in circulating adiponectin.

## Full-text entities

- **Genes:** ADIPOQ (adiponectin, C1Q and collagen domain containing) [NCBI Gene 9370] {aka ACDC, ACRP30, ADIPQTL1, ADPN, APM-1, APM1}, MSTN (myostatin) [NCBI Gene 2660] {aka GDF8, MSLHP}, CXCL8 (C-X-C motif chemokine ligand 8) [NCBI Gene 3576] {aka GCP-1, GCP1, IL8, LECT, LUCT, LYNAP}, INS (insulin) [NCBI Gene 3630] {aka IDDM, IDDM1, IDDM2, ILPR, IRDN, MODY10}, ETS1 (ETS proto-oncogene 1, transcription factor) [NCBI Gene 2113] {aka ETS-1, EWSR2, c-ets-1, p54}, CFAP97 (cilia and flagella associated protein 97) [NCBI Gene 57587] {aka KIAA1430, hmw}, ADIPOR2 (adiponectin receptor 2) [NCBI Gene 79602] {aka ACDCR2, PAQR2}, ETS2 (ETS proto-oncogene 2, transcription factor) [NCBI Gene 2114] {aka ETS2IT1}, CMPK1 (cytidine/uridine monophosphate kinase 1) [NCBI Gene 51727] {aka CK, CMK, CMPK, UMK, UMP-CMPK, UMPK}, ADIPOR1 (adiponectin receptor 1) [NCBI Gene 51094] {aka ACDCR1, CGI-45, CGI45, PAQR1, TESBP1A}, TERT (telomerase reverse transcriptase) [NCBI Gene 7015] {aka CMM9, DKCA2, DKCB4, EST2, PFBMFT1, TCS1}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}
- **Diseases:** muscle ischemia (MESH:D007511), fatigue (MESH:D005221), overweight (MESH:D050177), injury to (MESH:D014947), muscle damage (MESH:D009133), inflammatory (MESH:D007249), lipid (MESH:D011017), Muscle soreness (MESH:D063806), muscle membrane damage (MESH:D015433), musculoskeletal injury (MESH:D009140), adiposity (MESH:D018205), toxicity (MESH:D064420), muscle hypertrophy (MESH:C536106)
- **Chemicals:** Laemmli buffer (MESH:C088816), SDS (MESH:D012967), water (MESH:D014867), glucose (MESH:D005947), alcohol (MESH:D000438), lipid (MESH:D008055), creatine (MESH:D003401), fatty acid (MESH:D005227), caffeine (MESH:D002110), anabolic drugs (-)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12938250/full.md

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12938250/full.md

## References

31 references — full list in the complete paper: https://tomesphere.com/paper/PMC12938250/full.md

---
Source: https://tomesphere.com/paper/PMC12938250